Cephalon is once again on the acquisition trail
Tesaro of Waltham, Mass., a tiny biotech now preparing for its initial public offering, just licensed a promising anti-cancer drug from Merck
Partners of the UK’s National Cancer Research Institute (NCRI) spent more than £500 million on cancer research last year, nearly double the amount spent almost 10 years ago, says a new report.
Molecular diagnostics is the use of molecular biology for medical testing and clinical applications. This discipline determines how genes and proteins interact in a cell. This partnering article reflects on the recent life science trends in the molecular diagnostics technology arena.
AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer.
Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list
Sorry, your search returned no results.
Clovis Oncology have entered into a clinical trial collaboration with GlaxoSmithKline to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC)
Ventana Medical Systems has entered into a collaboration agreement with Pfizer to develop the first fully automated and standardized immunohistochemistry (IHC) companion diagnostic test for ALK gene rearrangements.
Agreement for large-scale process development and clinical manufacturing of ficlatuzumab
Abbott will develop a companion diagnostic test that will determine a patient’s genetic status and will be used in patient selection for future clinical trials of PF-02341066.
Formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia.
Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat, an investigational epigenetic therapy, with KEYTRUDA
Eli Lilly and Innovent Biologics announced one of the largest biotech drug development collaborations in China to date between a multi-national and domestic company
The National Comprehensive Cancer Network Oncology Research Program recently awarded five research grants in a pharma partnering venture, to investigators following NCCN ORP Scientific Review Committee analysis of proposals submitted in response to the NCCN Afatinib Request for Proposals.